Bioactive Glass Fiber Matrix: When to Add It
Reviving Stalled Wounds with Boron‑Based Bioactive Glass Fiber Matrix: What Clinicians Should Know
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always use your clinical judgment and local protocols.
Why stalled wounds are so hard to restart
Chronic and complex wounds are among the most expensive, frustrating problems in modern health care, especially in older and medically fragile patients who struggle with edema, diabetes, vascular disease, or systemic illness.[1,3]
The concept of wound bed preparation and the TIME/TIMERS frameworks were created precisely because so many wounds stall—stuck in chronic inflammation with slough, biofilm, and excess proteases blocking normal healing.[1,2]
When good basics (debridement, infection control, moisture balance, off‑loading, compression) still don’t move the needle, guidelines suggest considering advanced therapies such as cellular/tissue-based products (CTPs) or synthetic matrices to “reboot” the healing cascade.[3,4]
Boron‑based bioactive glass fiber matrices (BBGFM) are one of the newer synthetic options in this space—a fully resorbable glass microfiber scaffold engineered to support granulation, angiogenesis, and faster closure in hard‑to‑heal wounds.[4,7]
What is a boron‑based bioactive glass fiber matrix?
BBGFM dressings are made from bioactive glass that contains boron and other oxides, drawn into micro‑ to nanoscale fibers and formed into a soft, non‑woven mat that conforms closely to the wound bed.[6,7]
Once in contact with wound fluid, the glass fibers gradually dissolve and release ions such as calcium, sodium, phosphorus, and boron, creating a transient alkaline microenvironment and delivering signaling ions that interact with local cells.[5,10]
Preclinical work shows borate‑based glass fibers can stimulate vascular endothelial growth factor (VEGF) production, promote endothelial tube formation, and generally enhance angiogenesis and soft‑tissue regeneration—mechanisms that align with the rapid granulation many clinicians observe at the bedside.[5,10]
Because these matrices are fully synthetic and bioresorbable, they avoid the disease‑transmission concerns of human or animal grafts and do not require removal; instead, they are gradually replaced by native tissue as healing progresses.[6,8]
Why stalled wounds need more than “better dressings”
TIME/TIMERS teaches that chronic wounds often fail because of persistent non‑viable tissue, unmanaged inflammation or infection, excess moisture, and non‑advancing edges—problems that standard gauze or simple foams can’t fix alone.[1,3]
Extending TIME, Leaper and colleagues emphasized that chronic wounds should be reassessed holistically and escalated when progress is unsatisfactory, while the TIMERS update adds Regeneration and Social factors—explicitly recognizing when advanced regenerative materials and patient‑level barriers need to be addressed.[2,3]
In practice, that means once a wound has failed to show meaningful percent area reduction after several weeks of optimized standard care, it’s reasonable to ask whether the wound bed needs a more active scaffold—like a bioactive glass fiber matrix—to re‑start healing.[3,4]
Inside the case series: three complex patients whose wounds were “stuck”
The “Reviving Stalled Wounds” case series you shared describes three medically complex patients with non‑healing wounds that had plateaued despite appropriate standard interventions; each was transitioned to BBGFM with serial photographic and measurement follow‑up.[11]
Case 1 – 93‑year‑old with traumatic leg laceration: A lower‑extremity laceration from a cardboard box remained open in a very frail nonagenarian until BBGFM was initiated on 2/21/2025; complete closure occurred by 4/25/2025—about 9 weeks from matrix start.[11]
Case 2 – 64‑year‑old with foot abscess and severe systemic disease: This patient had a right foot abscess plus alcohol‑related portal hypertension, acute renal failure, and ascites. After multiple procedures and prolonged hospitalization, BBGFM was started on 5/31/2024, with full closure documented by 9/20/2024 (16 weeks).[11]
Case 3 – 52‑year‑old post‑arthroplasty wound post‑MVC: A non‑healing wound following joint arthroplasty and motor vehicle trauma showed minimal progress for months, then achieved a 47.74% percent area reduction with robust granulation and epithelialization within six weeks of BBGFM application (11/1/2024–12/13/2024), at which point it was ready for definitive closure.[11]
Across these three very different etiologies—trauma, deep infection in a systemically ill patient, and post‑surgical orthopedic breakdown—BBGFM either carried wounds to full closure or clearly reactivated healing after stagnation, suggesting a common effect on wound‑bed biology rather than an etiology‑specific phenomenon.[4,11]
How does this align with the broader evidence on BBGFM?
In a multi‑centre, single‑blinded randomized controlled trial of diabetic foot ulcers (DFUs), Armstrong et al. found that adding a resorbable glass microfiber matrix (Mirragen®/BBGFM) to standard of care significantly increased the proportion of ulcers healed at 12 weeks compared with standard care alone.[4]
A newer randomized trial in non‑healing Wagner grade 1 DFUs similarly reported that a borate‑based bioactive glass matrix accelerated closure and improved percent area reduction versus control dressings, reinforcing that the observed benefits are not limited to isolated case series.[9]
Preclinical studies show that borate‑based glasses stimulate VEGF secretion and drive angiogenesis, while regulated ionic dissolution products can be tuned to optimize fibroblast and endothelial cell responses—mechanistic data that matches the brisk granulation and epithelialization seen clinically.[5,10]
Reviews of bioactive glass–based fibrous wound dressings highlight additional advantages: inherent antimicrobial effects, beneficial pH shifts, modulation of inflammatory cells, and a porous scaffold that encourages cell infiltration and matrix deposition in soft tissue.[7,8]
Practical pearls for clinicians thinking about BBGFM
The TIMERS framework is a useful checklist before reaching for BBGFM: have you optimized Tissue (debridement), Inflammation/Infection, Moisture balance, and Edge advancement—and considered Regeneration and Social factors like off‑loading, nutrition, and adherence?[1,3]
In both the DFU RCT and the case series, BBGFM was used on top of standard care that included sharp debridement, infection management, exudate control, and appropriate off‑loading or compression, underscoring that it is an adjunctive wound‑bed therapy, not a stand‑alone cure.[4,11]
Once the wound bed is clean and reasonably well perfused, the matrix is trimmed to fit, placed into close contact with the wound surface, and covered with an appropriate secondary dressing; repeated applications are generally performed at weekly or bi‑weekly intervals until the wound is clearly progressing or closed.[4,7]
Because BBGFM is synthetic and resorbable, it can be a good option when patients or institutions prefer to avoid human or animal allografts, or when depth and complexity make frequent debridement plus temporary scaffolding more realistic than immediate flap or graft procedures.[6,8]
Which stalled wounds might benefit from a boron‑based glass matrix?
TIMERS consensus authors and DFU trialists both emphasize escalation when a wound fails to show ~30–50% percent area reduction after four to six weeks of optimized standard care, especially in patients with multiple comorbidities.[3,4]
Examples where BBGFM may be worth consideration include frail elderly patients with traumatic lower‑extremity wounds, individuals with severe systemic disease (e.g., liver failure, renal failure, or advanced heart disease), and complex post‑surgical wounds where vascular supply is adequate but the bed remains pale and stalled—scenarios very similar to the three cases in this series.[7,11]
Bottom line
Hard‑to‑heal wounds demand more than frequent dressing changes—they require a structured wound‑bed assessment (TIME/TIMERS) and timely escalation to advanced therapies when progress stalls despite good fundamentals.[1,3]
The Reviving Stalled Wounds case series adds to growing evidence from randomized trials and preclinical studies that boron‑based bioactive glass fiber matrices can help “reboot” healing in certain chronic or complex wounds, even in very medically fragile patients.[4,11]
For wound clinicians, the practical takeaway is to view BBGFM as a resorbable, infection‑resilient scaffold that supports angiogenesis and high‑quality granulation—best used once you’ve optimized the basics and need a way to re‑start a stalled wound’s healing cascade.[5,7]
References
Schultz GS, Sibbald RG, Falanga V, et al. (2003). “Wound bed preparation: a systematic approach to wound management.” Wound Repair and Regeneration, 11(Suppl 1), S1–S28. Link
Leaper DJ, Schultz G, Carville K, et al. (2012). “Extending the TIME concept: what have we learned in the past 10 years?” International Wound Journal, 9(Suppl 2), 1–19. Link
Atkin L, Bućko Z, Conde Montero E, et al. (2019). “Implementing TIMERS: the race against hard‑to‑heal wounds.” Journal of Wound Care, 28(Suppl 3a), S1–S50. Link
Armstrong DG, Orgill DP, Galiano RD, et al. (2022). “A multi‑centre, single‑blinded randomised controlled clinical trial evaluating the effect of resorbable glass fibre matrix in the treatment of diabetic foot ulcers.” International Wound Journal, 19(4), 791–801. Link
Chen S, Yang Q, Brow RK, et al. (2017). “In vitro stimulation of vascular endothelial growth factor by borate‑based glass fibers under dynamic flow conditions.” Materials Science and Engineering C, 73, 447–455. Link
Miguez‑Pacheco V, Hench LL, Boccaccini AR. (2015). “Bioactive glasses beyond bone and teeth: emerging applications in contact with soft tissues.” Acta Biomaterialia, 13, 1–15. Link
Homaeigohar S, Tsai TY, Young TH, et al. (2022). “Bioactive glass‑based fibrous wound dressings.” Burns & Trauma, 10, tkac038. Link OUP Academic
Negut I, Dorcioman G, Grumezescu V, et al. (2023). “Bioactive glasses for soft and hard tissue healing: an overview.” Applied Sciences, 13(10), 6151. Link
Armstrong DG, Galiano RD, Orgill DP, et al. (2025). “A borate‑based bioactive glass advances wound healing in non‑healing Wagner grade 1 diabetic foot ulcers: results from a randomized clinical trial.” International Wound Journal. Link
Decker S, Hupa L, Soltesz U, et al. (2022). “In vitro and in ovo impact of the ionic dissolution products of bioactive glasses on angiogenesis.” Scientific Reports, 12, 8820. Link
Escobar D. (2025). “Reviving Stalled Wounds: A Case Series on the Clinical Impact of a Boron‑Based Bioactive Glass Fiber Matrix in Complex Patients (CS‑031).” SAWC case‑series abstract; data on file (PDF provided by author/institution; not yet publicly indexed).
